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Background/Aims
Patients with diabetes mellitus (DM) often suffer from gastrointestinal (GI) symptoms, but these correlate poorly to established 
objective GI motility measures. Our aim is to perform a detailed evaluation of potential measures of gastric and small intestinal motility 
in patients with DM type 1 and severe GI symptoms. 
Methods
Twenty patients with DM and 20 healthy controls (HCs) were included. GI motility was examined with a 3-dimensional-Transit capsule, 
while organ volumes were determined by CT scans. 
Results
Patients with DM and HCs did not differ with regard to median gastric contraction frequency (DM: 3.0 contractions/minute 
[interquartile range {IQR}, 2.9-3.0]; HCs: 2.9 [IQR, 2.8-3.1]; P = 0.725), amplitude of gastric contractions (DM: 9 mm [IQR, 8-11]; 
HCs: 11 mm (IQR, 9-12); P = 0.151) or fasting volume of the stomach wall (DM: 149 cm3 [IQR, 112-187]; HCs: 132 cm3 [IQR, 107-154]; 
P = 0.121). Median gastric emptying time was prolonged in patients (DM: 3.3 hours [IQR, 2.6-4.6]; HCs: 2.4 hours [IQR, 1.8-2.7]; 
P = 0.002). No difference was found in small intestinal transit time (DM: 5 hours [IQR, 3.7-5.6]; HCs: 4.8 hours [IQR, 3.9-6.0]; P = 
0.883). However, patients with DM had significantly larger volume of the small intestinal wall (DM: 623 cm3 [IQR, 487-766]; HCs: 478 
cm3 [IQR, 393-589]; P = 0.003). Among patients, 13 (68%) had small intestinal wall volume and 9 (50%) had gastric emptying time 
above the upper 95% percentile of HCs. 
Conclusion
In our study, gastric emptying time and volume of the small intestinal wall appeared to be the best objective measures in patients with 
DM type 1 and symptoms and gastroenteropathy.
(J Neurogastroenterol Motil 2021;27:390-399)
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Introduction  
Gastrointestinal (GI) symptoms are common in patients with 
diabetes mellitus (DM).1 Their severity ranges from mild dis-
comfort to recurrent vomiting, chronic nausea, abdominal pain, 
diarrhea, or constipation.1,2 Severe GI symptoms are associated 
with reduced quality of life and cause significant burden on the 
healthcare system.3 Diabetic dysmotility can affect all segments of 
the GI tract and specific symptoms do not correlate well with the 
underlying pathophysiology.4 Autonomic neuropathy of the extrinsic 
vagal fibers and the intrinsic enteric nervous system is considered 
the primary cause of dysmotility in DM. Unfortunately, the auto-
nomic and enteric nervous systems are difficult to evaluate in vivo. 
Although tests of cardiovascular function are used as proxy for GI 
neuropathy, results correlate poorly with GI symptoms.5,6
Patients with symptoms attributed to the upper GI tract will 
usually undergo gastric emptying tests. The gold standard is gastric 
emptying scintigraphy, in which a standardized radiolabeled meal is 
tracked 30 minutes after ingestion and then every hour for at least 
4 hours.7 Limitations of this method include: high cost, radiation 
exposure, and poor correlation to symptoms.8,9 The wireless motil-
ity capsule (WMC) overcomes some of these limitations. It allows 
minimally invasive, ambulatory, radiation-free, and pan-enteric 
assessment of total and regional GI transit times.4,10-12 However, 
symptoms of gastroparesis, such as nausea, vomiting, bloating, and 
early satiety, show uncertain correlation to transit times found with 
the WMC.11,12 It is therefore plausible that other parameters than 
gastric emptying time and intestinal transit times should be consid-
ered as future diagnostic tests of GI dysfunction in DM.
With the Motilis 3-dimensional (3D)-Transit system (Motilis 
Medica SA, Lausanne, Switzerland) an electromagnetic capsule 
is followed as it traverses the GI tract. Like the WMC, the 3D-
Transit provides ambulatory assessment of gastric emptying, small 
intestinal transit time, and colonic transit time.13-15 Because the 3D-
Transit detects the exact anatomical position and orientation of the 
capsule at a sampling rate of 5-10 per second, the method allows 
detailed description of contraction parameters. Recent development 
of the software for post processing of data now provides informa-
tion not only on the frequency, but also on the amplitude of gastric 
contractions.
Earlier studies have found increased small intestinal volume in 
diabetic rats.16-18 In humans, small intestinal volume can be mea-
sured from a low-dose CT scan or by MRI. In spite of this, gastric 
and small intestinal volumes have received little attention as mea-
sures of diabetic enteropathy.
In the present explorative study, we aim at comparing (1) the 
basic gastric contraction rate, (2) the amplitude of gastric contrac-
tions, (3) gastric emptying time, (4) volume of the stomach, (5) 
small intestinal transit time, and (6) volume of the small intestine in 
patients with DM and GI symptoms with those of healthy controls 
(HCs).
Materials and Methods  
Subjects
Between September 2015 and May 2019, 20 adult patients (11 
males; mean age, 46.5 [standard deviation {SD}, 12.2]) with DM 
type 1 and severe GI symptoms and 20 age and sex-matched HCs 
(11 males; mean age, 45.0 [SD, 10.6]) were enrolled. The patients 
had been referred to our tertiary clinic because of chronic GI symp-
toms attributed to long-term diabetes. No formal symptom-based 
definition of diabetic gastroenteropathy exists, but all patients were 
evaluated by an experienced specialized neurogastroenterologist 
(M.W.K.) and screened for the present study if their symptoms 
were considered severe enough to warrant further clinical evalua-
tion. All patients had symptoms which could be attributed to the 
upper GI tract but most also had symptoms usually originating 
from the colon. All participants signed a written informed consent 
before enrollment and all patients had a total score in Gastroparesis 
Cardinal Symptom Index (GCSI) above 10.19,20
Exclusion criteria were: previous intestinal resection or other 
major abdominal surgery, other diseases affecting GI function, and 
severely reduced kidney or cardiac function. Due to radiation expo-
sure incurred by CT scans, fertile women had to present a negative 
pregnancy test before participating. All medications affecting the 
GI function were paused at least 48 hours before each investiga-
tion. As a part of the standard diagnostic workup, all patients had 
been evaluated with gastroscopy, standard blood and stool tests 
for inflammatory bowel disease, celiac disease, lactose intolerance, 
thyroid disease, malabsorption, and GI infection. Also, on clinical 
indication, gastric emptying scintigraphy had been performed in 14 
patients.
The study was conducted according to the Helsinki declaration 
and European Community rules of good clinical practice. Approval 
was obtained from the scientific ethics committee (reference: 1-10-
72-54-15) and the medical authorities (reference: 2016101143).
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Assessment of Diabetic Autonomic Neuropathy
Cardiac autonomic neuropathy (CAN) was assessed using the 
handheld medical device Vagus (Medicus Engineering, Aarhus, 
Denmark). CAN is routinely used as a surrogate marker of auto-
nomic neuropathy in patients with diabetes. CAN was defined by 
using gold standard cardiovascular reflex tests including the heart 
response: to standing from a supine position, to deep breathing, and 
to forceful expiration (normal cardiovascular reflex tests, no CAN; 
one abnormal cardiovascular reflex test, early CAN; and autonomic 
dysfunction, 2 or 3 abnormal cardiovascular reflex tests, manifest 
CAN). Age-dependent cutoffs were used to define abnormal 
results.21 Twenty-four hour blood pressure had been recorded on 
clinical request. Attenuated decrease (dip) in the nocturnal blood 
pressure of less than 10% was considered abnormal. Periphery neu-
ropathy was assessed with monofilament according to international 
guidelines.22 Furthermore, patients were asked about their sensation 
of hypoglycemia. The answers were categorized as “preserved,” 
“poor,” or “no sensation.”
Assessment of Gastric Contraction Frequency, 
Amplitude, and Emptying Time
The 3D-Transit system is a wireless electromagnetic capsule 
system used for detailed assessment of GI motility patterns and 
transit times.13-15,23,24 After an overnight fast, the extracorporeal de-
tector was mounted and the electromagnetic capsule (21.5 mm × 
8.3 mm, 1.6 g/cm3) ingested with a standardized meal (2 granola 
bars: total 250 kcal; protein 3.8 g, fat 7.4 g, and carbohydrate 42 g; 
and 300 mL of water). The detector belt was worn from inges-
tion until capsule expulsion from the body or end of battery power. 
However, subjects under study were allowed to remove the detector 
briefly when showering. They were not allowed to do heavy exer-
cise, or stay closer than 40 cm to a computer during the study. Oth-
erwise, all normal daily routines could be followed. Patients wearing 
an insulin pump or blood glucose sensor were hospitalized and had 
the device removed the day before starting the 3D-Transit examina-
tion. This precaution was taken to avoid interaction between the 
3D-Transit system and the medical devices. Blood glucose was ad-
justed with manual insulin injections supervised by an experienced 
endocrinologist (S.L.). The blood glucose was targeted to be within 
the interval of 5-10 mmol/mL.
With 3D-Transit, the electromagnetic field emitted by the 
capsule is registered by the detector and data is converted into co-
ordinates (x, y, z, ɸ, and q) via an iterative algorithm. The x, y, and 
z coordinates define spatial 3D position while ɸ, and q express the 
angular position of the capsule to the detector. The lifetime of the 
battery within the capsule is approximately 60 hours.
Recordings were analyzed in a custom developed software 
to calculate regional transit times and contractility patterns.13 As 
previously described in detail, gastric emptying and small intestinal 
transit times were defined from region-specific contraction frequen-
cies and the changes in position of the capsule on 2D plots.13 All 
gastric contractions were manually marked to calculate frequency, 
amplitude, and percentage of time with visible gastric contractions. 
Analysis of gastric contractions was restricted to the first 6 hours 
after the index meal because subjects were allowed to eat after this 
period of time. All analyses were independently made by 2 investi-
gators (M.W.K. and A.M.H.). In case of disagreement, the mean 
value was used.
Volumes of the Stomach and Small Intestine
A low-dose high-resolution CT scan with intravenous contrast 
(Visipaque 270 mg/mL; 2 mL/kg body weight with a maximum 
of 180 mL) was performed after a minimum of 6 hours fasting for 
food and a minimum of 2 hours for liquids. The scan field covered 
an area from the left cardiac ventricle to the lower part of the anal 
canal allowing assessment of abdominal organ volumes as well as 
gas and fluid volumes within the gut. Data analysis was performed 
in PMOD version 3.6 (PMOD Technologies, Zurich, Switzer-
land). Regions of interest were manually defined on each slice of 
the CT scan. Volumes-of-interest were computed by fusing all the 
regions of interest. Water/fluid was defined by Hounsfield unit < 30 
for water and < –200 Hounsfield units for gas.25 The investigator 
making all analyses (M.W.K.) was blinded to clinical category of 
the test subjects. Part of the volume data will be presented else-
where.26
Assessment of Gastrointestinal Symptoms
GI symptoms were assessed by the following 3 validated ques-
tionnaires: (1) Symptoms from the upper GI tract were quanti-
fied by the 20 item Patient Assessment of Upper Gastrointestinal 
Symptom Severity Index (PAGI-SYM) questionnaire.20 The 
PAGI-SYM questionnaires consists of 6 subscales: heartburn/re-
gurgitation, nausea/vomiting, fullness/early satiety, bloating, upper 
abdominal pain, and lower abdominal pain, each ranging from 0 
(minimum) to 5 (maximum severity). (2) Symptoms of gastropa-
resis were rated by the GCSI, which is a 9-item score derivate from 
PAGI-SYM.19 (3) The severity of constipation was quantified by 
the 8 item Constipation Score System.27
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Statistical Methods
Three-dimensional Transit data were prepared for analysis by a 
custom-made file in MATLAB version 2018b (MathWorks Inc, 
Natick, MA, USA). Statistical analysis was performed in Stata 
statistical software version 2013 (StataCorp LLC, College Station, 
TX, USA). Graphic illustrations were performed using Prism 8 
(GraphPad Software, San Diego, CA, USA). Parametric data were 
compared with two-way unpaired Student’s t test with Welch cor-
rection for unequal variance. Nonparametric data were compared 
by means of Wilcoxon Mann-Whitney U test. P < 0.05 was con-
sidered significant.
Results  
Among 128 patients with DM referred to our unit because of 
GI symptoms, 20 fulfilled the inclusion criteria and were willing to 
participate. Reasons for non-participation were: concomitant disease 
(n = 65), concomitant medication (n = 27), previous surgery (n = 4), 
uncertain symptoms (n = 7), declined study participation (n = 8), 
and non-compliance (n = 4). A few patients had more than one 
reason for non-participation. Patients’ demography is displayed in 
Table 1 and clinical characteristics obtained from the questionnaires 
in Table 2. Results from the diabetes neuropathy test are shown in 
Tables 1 and 3.
Table 1. Demographics and Clinical Characteristics of Patients and Healthy Controls Included in the Study
Demographics Patients with DM type 1 Healthy controls P-values
Participants (M/F) 11/9 11/9 1.000
Age (yr) 46.5 (12.2) 45.0 (10.6) 0.675
Duration of GI symptoms (mo) 42.0 (30.7)
Duration of diabetes (yr) 27.3 (12.7)
BMI (kg/m2) 23.3 (22.1-26.9) 26.3 (24.2-27.1) 0.083
Glomerular filtration rate (mL/min/1.73 m2) 89.4 (25.6) 97.3 (18.8) 0.304
Urine albumine-creatinine ratio 10.5 (5.0-33.0)
Hemoglobin A1C (%) 8.4 (1.8)
Fast acting insulin (IU/kg per day) 24.3 (8.9)
Slow-acting insulin (IU/kg per day) 25.2 (14.9)
Insulin pump 5 (25%)
Insulin sensor 6 (30%)
Diabetic eye disease 12 (60%)
Heart disease 2 (11%)
Lack of noctunal blood pressure dip 4 (20%)
DM, diabetes mellitus; M, male; F, female; GI, gastrointestinal; BMI, body mass index; IQR, interquartile range.
Data are presented as mean (SD), medians (interquartile range [IQR]), or n (%).
Table 2. Clinical Characteristics of the Questionnaires Patients and Healthy Controls Included in the Study
Clinical questionnaires Patients with DM type 1 Healthy controls P-values
PAGI-SYM 35.6 (22.9) 5.6 (6.6) < 0.001
GCSI 17.85 (9.27) 3.1 (3.8) < 0.001
  Sub-score
    Bloating
    Nausea/vomiting










CSS 10 (4.9) 4.4 (3.2) < 0.001
DM, diabetes mellitus; PAGI-SYM, patient assessment of upper gastrointestinal symptom severity index; GCSI, gastroparesis cardinal symptom index; CSS, con-
stipation scoring system.
Data are presented as mean (SD) or medians (interquartile range [IQR]).
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of healthy
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of healthy
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Sensation of  
hypoglycemia
5 No Yes Yes - - Yes No
11 Yes No No Normal No No Poor
12 Yes No Yes Prolonged - No Yes
15 Yes Yes Yes - Yes - -
15 No No Yes Normal No No Yes
18 No No No Normal No No Yes
19 No No Yes - No No Yes
21 - Yes Yes - No No -
22 Yes Yes Yes Prolonged No Yes -
28 No No Yes Normal Yes No Yes
28 Yes - - Normal Yes Yes No
32 Yes No No Normal No No Poor
33 No No Yes - No No Yes
34 Yes No No Normal No Yes No
36 Yes No No Normal No Yes Poor
37 No Yes Yes Normal No Yes Yes
40 Yes Yes Yes Prolonged Yes - Poor
45 - No Yes - - No Yes
45 No Yes Yes Prolonged No - Yes
49 No No No Normal Yes Yes No
9 (50%) 7 (37%) 13 (68%) 4 (29%) 5 (29%) 7 (41%) 8 (47%)
DM, diabetes mellitus.










































































Figure 1. Intragastric movements of the 3-dimensional Transit electromagnetic capsule. Recordings from a healthy volunteer (A) and a patient 
with diabetes (B). Red dots show every 30 minute intervals position in the stomach.
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Gastric Contractions
Median time with recognizable contractions of the stomach 
was 92% (interquartile range [IQR], 79-94) in patients with 
DM and 92% (IQR, 78-97) in HCs (P = 0.501). The median 
frequency of gastric contractions was 3.0 contractions per minute 
(CPM) (IQR, 2.9-3.0) in patients with DM and 2.9 CPM (IQR, 
2.8-3.1) in HCs (P = 0.725). The median amplitude of capsule 
rotation was 27 degrees (IQR, 19-41) in patients with DM and 31 
degrees (IQR, 23-42) in HCs (P = 0.736). The median ampli-
tude of change in position of the capsule was 9 mm (IQR, 8-11) in 
patients with DM and 11 mm (IQR, 9-12) in HCs (P = 0.151). 
In 2 (10%) patients with DM the amplitude (position) of gastric 
contractions was below the lower 5% limit of HCs. Examples of in-
tragastric movements in a patient with DM and in a HC are shown 
in Figure 1.
Gastric Emptying Time
Median gastric emptying time was 3.3 hours (IQR, 2.6-4.6) 
in patients with DM and 2.4 hours (IQR, 1.8-2.7) in HCs (P = 
0.002). In 9 (50%) of 18 patients, gastric emptying time was be-
yond the upper 95% limit of the HC group (Table 3).
Gastric Volume
There was no difference in gastric wall volume between patients 
with DM and HCs (Fig. 2 and Table 4). In 7 of 19 patients (37%), 
the volume of the gastric wall was above the upper 95% percentile 
of HCs. The amount of fluid in the stomach and the total volume 
of the stomach including both the wall and luminal content did not 
differ significantly between the 2 groups (Table 4).
Small Intestinal Transit Time
Median small intestinal transit time was 5.0 hours (IQR, 3.7-
5.6) in patients with DM and 4.8 hours (IQR, 3.9-6.0) in HCs 
(P = 0.883). In 2 of 19 patients (11%), small intestinal transit time 
was above the upper 95% limit of the HC group.
Volume of the Small Intestine
As illustrated in Figure 2 and seen in Table 4, patients with 
DM had significantly larger volume of the small intestinal wall. 
In 13 of 19 patients (68%), the small intestinal wall volume was 
above the upper 95% limit of that in HCs (Table 3). The total small 
intestinal volume including both the wall and luminal content was 
likewise significantly larger in patients with diabetes. DM patients 
had more fluid in the small intestine compared to HCs, but the dif-
ference did not reach statistical significance (Table 4).
Questionnaires
In all questionnaires, patients with DM scored significantly 
































Volume of the small intestine
0
Figure 2. Volumes of the gastric (A) and small intestinal walls (B) as-
sesses with CT scans. The horizontal line shows the median. Diabetes 
patients had a significantly larger volume of the small intestinal wall 
(P = 0.003) but not of the stomach (P = 0.121). HCs, healthy con-
trols; DM, patients with diabetes mellitus. 
Table 4. Gastric and Small Intestinal Volumes
Gastrointestinal volumes (cm3) Healthy controls Patients with diabetes P-value
Volume of the stomach including luminal content 182 (151-246) 162 (138-193) 0.078
Volume of the gastric wall 131 (107-154) 149 (112-187) 0.121
Volume of fluid in the stomach 31 (17-56) 37 (24-84) 0.293
Volume of the small intestine including gas and luminal content 713 (639-899) 927 (829-1051) 0.002
Volume of the small intestine wall 478 (393-589) 623 (487-766) 0.003
Volume of fluid in the small intestine 209 (165-236) 227 (191-288) 0.082
Volume of gas in the small intestine 95 (40-150) 83 (56-139) 0.872
Among patients with diabetes, 7 (37%) had a total small intestinal volume and 4 (21%) had a total gastric volume above the upper 95% percentile of healthy controls.
Data are presented as medians (interquartile range [IQR]).
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there was no association between any of the scores and the objective 
measures described above.
Discussion  
Symptoms of gastric and small intestinal dysfunction are com-
mon among patients with DM. In the present explorative study, 
we found no differences in basic gastric contraction frequency or 
the amplitude of gastric contractions when comparing patients with 
DM and HCs. Gastric emptying time, but not small intestinal 
transit time, was longer in patients with DM than in HCs. The 
volume of the small intestine was significantly larger in patients than 
in HCs. Hence, the main implications of our study are that gastric 
emptying time and small intestinal wall volume seem to be the most 
sensitive objective measures in patients with DM type 1 and symp-
toms of dysmotility within the upper GI tract.
Diabetic Enteropathy
Because of the non-specific symptoms, diagnosis of diabetic 
gastroenteropathy is difficult. The pathophysiology behind diabetic 
gastroenteropathy is incompletely understood. Enteric and vagal 
neuropathy, depletion of interstitial cells of Cajal, reduced function 
of smooth muscle cells, and hyperglycemia may all contribute to 
gastroenteropathy.28-32 The GI tract is innervated by sympathetic, 
parasympathetic, and enteric nerves. Animal studies have found 
morphological changes in the vagal nerve and segmental demyelin-
ation as well as axonal degeneration of the myenteric and submuco-
sal plexus.29-31 Products of glycation may cause neural damage and 
reduce neuronal nitric oxide synthase.33 Since neuronal nitric oxide 
synthase is reduced in early stage diabetic rats while cholinergic 
nerves are affected later, it has been suggested that inhibitory neu-
rons are affected by DM before excitatory.34 Both factors increase 
the risk of GI complications. Diabetic gastroparesis is usually diag-
nosed after 10 years of disease.35 In our study population, the mean 
duration of diabetes was more than 20 years and hemoglobin A1C 
was relatively high.
Standard Tests of Autonomic and Peripheral 
Neuropathy
Earlier studies have shown that autonomic, but not peripheral 
somatic neuropathy correlates with prolonged gastric emptying.8,36 
Hence, CAN is commonly used as a surrogate for enteric neuropa-
thy in patients with DM. CAN is easily assessed with 3 different 
cardiovascular reflex tests sometimes in combination with a 24-hour 
blood pressure measurement, but unfortunately the correlation with 
GI symptoms remains poor.5,8 In the present study, 29% patients 
with symptoms of diabetic enteropathy had manifest CAN. Bha-
rucha et al37 showed in 78 patients with DM type 1, that decreased 
heart rate variability in the deep breathing test and not the response 
to standing or the Valsalva maneuver, correlated with prolonged 
gastric emptying. Detailed heartrate variability analysis was not part 
of the primary endpoint and the possible association to prolonged 
gastric emptying will be investigated in a future study.
Gastric Contractions
Comparing the basic gastric contraction frequency, the ampli-
tude of contractions and the time with identifiable contractions, we 
found no difference between patients with DM and HCs. Previous 
studies of the myoelectrical activity assessed with electrogastrog-
raphy have shown discoordinated activity in patients with DM. 
This contrasts our results, but electrical impulses from the surface 
of the body may not entirely correlate with gastric contractions.38 
Also, in contrast to our data, a study of 113 subjects evaluated with 
the WMC found a decreased number of contractions per hour in 
patients with DM. The reduced number of contractions was as-
sociated with prolonged gastric emptying.39 The difference to our 
study may be due to a type II error caused by the smaller number of 
patients in our study.
We used the electromagnetic 3D-Transit system to describe 
gastric motility in detail. The 3D-Transit capsule is very sensitive as 
even millimeters of displacements in its position or a few degrees of 
rotation will be registered. Capsule location in the stomach fundus 
may change the contraction frequency. However, brief stays in the 
fundus were included in the total gastric contraction analysis, as 
the stays were short lasting and estimated without influence of the 
contractility pattern. Theoretically, changes in position are more 
sensitive than pressure changes, especially in large hollow organs. 
Hence, we expected that the 3D-Transit would add new and valu-
able information about gastric contractions not available with other 
methods. However, median values for the frequency of gastric con-
tractions were almost identical among patients with DM and HCs. 
The number of subjects included in the present study was too small 
to draw definite conclusions, but our data may suggest the basic 
frequency of myoelectrical activity generated by the smooth muscle 
cells was intact. The amplitude of movements of the capsule was 
lower in patients with DM than in HCs, but the difference did not 
reach statistical significance, which may be related to the relatively 
small sample. Previous studies have shown that DM causes im-
paired accommodation of the stomach, which may contribute to GI 
symptoms even if gastric contractions remain unaltered.40
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Gastrointestinal Transit Times
Patients with diabetic enteropathy have pan-enteric dysmotil-
ity and assessment of regional GI transit times is part of the clinical 
evaluation at many centers. The commonly used WMC is a radi-
ation-free, ambulatory and minimal invasive method that has been 
validated against scintigraphy and the 13C breath test.41 The 3D-
Transit system is not yet as well established as the WMC. How-
ever, gastric emptying and small intestinal transit time obtained by 
magnet tracking have been tested together with endoscopic video 
capsule (PillCam) and gastric emptying scintigraphy.24,42 The elec-
tromagnetic capsule for 3D-Transit is smaller (21.5 mm × 8.3 mm) 
than the WMC (26.8 mm × 11.7 mm) but normative data for 
regional transit times with the 2 methods are very similar. With the 
WMC, gastric emptying was more affected in DM than the small 
intestinal transit time.43 Thus, the previous studies with the WMC 
support the findings of the present study.
Volume of the Small Intestine
In previous studies, rats with DM had hyperplasia of the 
small intestine.16-18 This is probably mainly due to mucosal hyper-
trophy.44,45 In our study, patients with diabetes had a 34% increase 
of small intestinal wall volume compared to HCs. We found it 
noteworthy that 68% of patients with DM and symptoms of upper 
GI dysmotility had volumes of the small intestinal wall above the 
upper 95% limit of the HCs. Thus, assessment of small intestinal 
wall volume holds promise as a more sensitive marker of diabetic 
enteropathy than other existing methods. Unfortunately, assessment 
of intestinal volumes is time consuming and new techniques for this 
are warranted.
Limitations
The present study is an explorative study including 40 study 
participants in total. The small study size increases the risk of type 
II errors. Thus, a larger study is needed to confirm our findings. 
Furthermore, in future studies a control group of patients recently 
diagnosed with DM could be included. The patients included 
in the present study were selected from the much larger group of 
patients referred to our unit for assessment of diabetic enteropathy. 
This may have caused selection bias and therefore affect the external 
validity of the study findings. The main reasons for excluding pa-
tients from the study were use of medication influencing gut motil-
ity and nephropathy.
Gastric emptying scintigraphy was not part of our study proto-
col, but 14 patients had the procedure performed on clinical indica-
tions. A direct comparison between 3D-Transit or volume assessed 
by CT and gastric emptying scintigraphy would be highly relevant, 
as the latter is considered the gold standard test for gastric empty-
ing. Such comparison was however beyond the scope of the present 
study. There was discrepancy between results from gastric empty-
ing scintigraphy and the 3D-Transit capsule. Scintigraphy was not 
performed on the same days as the 3D-Transit study. Symptoms 
of diabetic enteropathy may fluctuate and there is intersubjective 
variation in objective methods used. Whether this is the cause of the 
discrepancy found or 3D-Transit is more sensitive than gastric emp-
tying scintigraphy needs to be addressed in larger studies. Finally, 
all patients in the present study had DM type 1 and results may not 
be directly applicable to patients with DM type 2.
In conclusion, in this present study the frequency of gastric 
contractions was unaffected by DM. Among the parameters stud-
ied, gastric emptying time and volume of the small intestine seem to 
provide the most sensitive objective measures in patients with DM 
type 1 and symptoms attributed to the upper GI tract.
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